CUSIP No. 270087109
SCHEDULE 13D
Item 1. | Security and Issuer. |
Reference is made to the statement on Schedule 13D filed on October 29, 2020 (the “Original Schedule 13D”) and relates to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Eargo, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 1600 Technology Drive, 6th floor, San Jose, CA 95110.
This Amendment No. 1 (the “Amendment”) hereby amends and supplements the Original Schedule 13D as described herein. Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth thereto in the Original Schedule 13D.
Item 2. | Identity and Background. |
Item 2 is amended and supplemented as follows:
(a) The securities of the Issuer reported herein are directly held by Pivotal Alpha and Permwell. Pivotal Alpha is wholly-owned by Eternal Sky, which is wholly-owned by Grand Epoch. Grand Epoch and Permwell are both wholly-owned by NFIHL, which is wholly-owned by NFGHL. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal Alpha and Permwell. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung,Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Pivotal Alpha, Eternal Sky and Grand Epoch each disclaims beneficial ownership of the securities reported herein as beneficially owned by Permwell and Permwell disclaims beneficial ownership of the securities reported herein as beneficially owned by Pivotal Alpha, Eternal Sky and Grand Epoch.
Item 3. | Source and Amount of Funds or Other Consideration. |
No changes.
Item 4. | Purpose of Transaction. |
Item 4 is amended and supplemented as follows:
Peter Bisgaard, who is a Managing Director of Nan Fung Life Sciences and a Managing Partner of Pivotal Bioventure Partners LLC (both affiliates of the Reporting Persons) resigned his position on the board of directors of the Issuer as of August 3, 2022.
Item 5. | Interest in Securities of the Issuer. |
Item 5 is amended and supplemented as follows:
(a)-(b) In addition, Peter Bisgaard directly beneficially owns (i) 41,970 shares of Common Stock, and (ii) a fully vested option to purchase 6,666 shares of Common Stock at an exercise price of $18.00 per share. Mr. Bisgaard resigned his position on the board of directors of the Issuer as of August 3, 2022. Mr. Bisgaard disclaims beneficial ownership of all securities reported as beneficially owned by the Reporting Persons, except to the extent of his pecuniary interest, if any, therein.
(e) On November 23, 2022, the Issuer issued a total of 375,000,000 shares of Common Stock in connection with a rights offering (the “Rights Offering”) and notes conversion. The Reporting Persons did not participate in the Rights Offering. As a result of the increase to the number of outstanding shares of Common Stock resulting from the Rights Offering, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Shares.